SLAMF6 and melanoma: In its absence, TCR triggering of anti-melanoma CD8+ T cells yielded a strong effector phenotype, higher IFN-γ secretion, improved cytolysis, and better outcomes in the adoptive transfer of SLAMF6 -/- anti melanoma CD8+ T cells to treat established melanoma.